1. Immunology/Inflammation
  2. CTLA-4 Interleukin Related
  3. JS007

JS007 是一种人源化 IgG1 单克隆抗体,同时也是 CTLA-4 结合剂,与 CTLA-4Kd 为 0.21 nM。JS007 阻断 CTLA-4/B7-1 的相互作用。JS007 可激活 T 细胞、促进 IL-2 分泌增加,并在 CTLA-4 敲入小鼠同源肿瘤模型中抑制肿瘤生长。JS007 可用于癌症及晚期实体瘤的相关研究。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

JS007

JS007 Chemical Structure

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 是否有货
1 mg   询价  
5 mg   询价  
10 mg   询价  

* Please select Quantity before adding items.

Customer Review

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

JS007 is a humanized IgG1 monoclonal antibody and also a CTLA-4 binder, with a Kd of 0.21 nM for CTLA-4. JS007 blocks the interaction between CTLA-4 and B7-1. JS007 activates T cells, promotes increased IL-2 secretion, and inhibits tumor growth in CTLA-4 knock-in mouse syngeneic tumor models. JS007 is applicable to research related to cancer and advanced solid tumors.[1][2]

同型

Human IgG1 kappa

推荐同型对照抗体
反应种属

Human/Mouse/Bovine

IC50 & Target[1]

IL-2

 

体外研究
(In Vitro)

JS007 可结合 CHO-CTLA-4 细胞,其 EC50 为 0.22 μg/mL,结合亲和力高于对照抗体 Ipilimumab (HY-P9901)[1]
JS007 与重组 CTLA-4 结合,其 KD 值为 0.21 nM,结合亲和力显著高于对照抗体 Ipilimumab[1]
JS007 可在 CHO-CTLA-4 细胞中阻断 CTLA-4/B7-1 的相互作用,其 IC50 为 1.096 μg/mL[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

JS007 (0.1-1 mg/kg;腹腔注射;每周两次) 在相同剂量下,相较于 Ipilimumab,能在携带 MC38 同源肿瘤的人源 CTLA-4 基因敲入 C57BL/6 小鼠中展现出更优异的体内肿瘤抑制效力,可使肿瘤体积和重量出现具有统计学意义的降低 (p < 0.05)[1]
JS007 (0.03-0.1 mg/kg;腹腔注射;每周两次) 可在携带 H22 同源肿瘤的人源 CTLA-4 敲入 BALB/c 小鼠中展现出显著的体内抑瘤功效,与同型对照组相比,其肿瘤体积和重量均出现具有统计学意义的降低 (p < 0.01)[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6-CTLA4tm1(CTLA4)/Bcgen[1]
Dosage: 0.1 mg/kg; 1 mg/kg
Administration: i.p.; twice weekly
Result: Showed significantly lower tumor volume and weight compared to the isotype control group at 1 mg/kg, with values also significantly lower than the ipilimumab 1 mg/kg group (p < 0.05).
Showed significantly lower tumor volume and weight compared to the isotype control group at 0.1 mg/kg, but higher tumor volume and weight than the 1 mg/kg JS007 group.
Animal Model: BALB/c-Ctla4em1(hCTLA4)Smoc[1]
Dosage: 0.03 mg/kg; 0.1 mg/kg
Administration: i.p.; twice weekly
Result: Showed substantially lower tumor volume and weight compared to the isotype control group at 0.1 mg/kg (p < 0.01).
Showed significantly lower tumor volume and weight compared to the isotype control group at 0.03 mg/kg, but higher tumor volume and weight than the 0.1 mg/kg JS007 group.
Showed a better tumor inhibition trend than ipilimumab at 0.1 mg/kg, though the difference was not statistically significant (p > 0.05).
基因 ID

1493  [NCBI]

Accession
靶点

CTLA4

应用

ELISA, FACS, Functional assay

偶联物

Unconjugated

复溶方法

The product can be reconstituted/diluted with sterile PBS or saline.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料
参考文献
  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
JS007
目录号:
HY-P991960
需求量: